Business & Finance
14 January 2025, 2:12 pm 1 minute
Reuters was two-and-a-half minutes ahead of rivals on Eli Lilly’s unscheduled trading update, which showed fourth-quarter sales of its weight-loss drug Zepbound would miss Wall Street estimates. The drugmaker’s shares slumped 8% on the news.
Article Tags
Topics of Interest: Business & Finance
Type: Reuters Best
Sectors: Business & Finance
Regions: Americas
Win Types: Speed
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Important Regional Story
